and other RTIs. Encounters with older patients took 0.62 minutes longer than those with patients aged 18 to 29 years. Physicians in the West took 1.05 minutes longer than those in the Northeast, and regional concordance between physician and patient was associated with visits that were 0.29 minutes longer.
Antiphospholipid Antibodies in Patients With Myocardial Infarction
Background: Antiphospholipid syndrome (APS) is defined by arterial, venous, or microvascular thrombosis or obstetric morbidity together with confirmed positive test results, at least 12 weeks apart, for antiphospholipid antibodies (aPLs), including at least 1 of the following tests: anticardiolipin (anti-CL), anti-␤ 2 -glycoprotein I (anti-␤ 2 GPI), or the functional lupus anticoagulant test (1, 2) . Long-term anticoagulation prevents new thrombotic events in most patients with APS. Information on prothrombotic aPLs in patients with myocardial infarction (MI) is conflicting, due to limited sample sizes, selected populations, and nonstandardized methods in previous studies (3) .
Objective: To assess the frequency of anti-␤ 2 GPI and anti-CL of IgG/IgA/IgM isotypes and antinuclear antibodies among patients with first-time MI and matched control participants in a large, multicenter, case-control study.
Methods and Findings: The PAROKRANK (Periodontitis and Its Relation to Coronary Artery Disease) study included 805 consecutive patients younger than 75 years who were hospitalized for a first MI at 17 Swedish hospitals between 2010 and 2014 (4). Population control participants (n = 805) were individually matched for age, sex, and region to the patients. Persons who had prior MI or heart valve replacement or were unable to follow the protocol were excluded.
Patients were recruited during hospitalization and scheduled for an inclusion visit 6 to 10 weeks later at their local cardiology clinic. The national quality registry SWEDEHEART (www.swedeheart.se) was used to collect medical information at the hospitalization and standardized follow-up data at the inclusion visit. More detailed clinical protocol and extensive questionnaires were also completed at the inclusion visit (5). The same information was collected for the matched control participants. All participants fasted and abstained from smoking for 12 hours before blood sampling at the inclusion visit.
Autoantibodies targeting CL and ␤ 2 GPI of IgG/IgM/IgA isotypes and specific nuclear antigens, as specified in the Table, were analyzed using multiplexed beads (BioPlex 2200 Multiplex Testing, Bio-Rad). The study was approved by the Regional Ethics Committee in Stockholm, Sweden (Dnr:2008/152-31/2), and all participants provided written informed consent.
The Table shows participant characteristics and laboratory results. We found that IgG anti-␤ 2 GPI and/or IgG anti-CL (referred to as aPL IgG positive) were more common in patients with MI (aPL IgG positive: n = 88 [11.1%]) than in control participants (n = 10 [1.3%]) (P < 0.001), whereas IgA/IgM isotypes did not differ. Many patients with MI had high IgG levels (Figure) . Anti-CL and anti-␤ 2 GPI of the same isotype correlated strongly (IgM: r s = 0.92; IgG: r s = 0.85; IgA: r s = 0.86).
In multivariable conditional logistic regression analysis (SAS software, version 9.4; SAS Institute) adjusted for traditional risk factors (Table) , aPL IgG positivity (odds ratio, 7.8 [95% CI, 4.0 to 15.3]; P < 0.001) and current smoking (odds ratio, 2.6 [CI, 1.9 to 3.5]; P < 0.001) remained associated with MI, whereas diabetes, hypertension, and body mass index did not.
Using t tests and 2 tests as appropriate, we found that age did not differ among aPL IgG-positive (n = 88) and -negative (n = 704) patients with MI (63.1 vs. 61.8 years; P = 0.146), but aPL IgG positivity was nonsignificantly more common among women (26.1% vs. 17.9%; P = 0.062) and current smokers (33.7% vs. 25.1%; P = 0.085).
Discussion: We report a high prevalence (11%) and strong positive associations between aPL IgG positivity and first-time MI. These antibodies were 10 times more common in patients with MI than control participants, and they occurred independently of traditional cardiovascular risk factors. Notably, only aPLs of the IgG isotype were elevated. No differences between patients with MI and control participants regarding IgM, included in the Sydney criteria (1), or IgA were observed.
Blood samples were drawn 6 to 10 weeks after MI, so whether the antibodies were present before the MI or whether they were persistent or transient are unknown. Persistent aPLs together with MI would indicate definite APS (1), for which current guidelines recommend indefinite warfarin treatment (2) . Transient aPLs might represent an immunologic reaction to myocardial damage during MI or an infection, and whether these aPLs are associated with enhanced risk for thrombosis is not known.
This study includes a large and representative study population with first-time MI, both sexes, and well-matched control participants. It used standardized methods for aPL measurements and collection of participant characteristics. Study limitations are that aPL determinations were investigated only once and that the lupus anticoagulant test could not be performed due to lack of citrated plasma. A strong and independent association between aPL IgG positivity and first-time MI may represent an important, but until now neglected, risk factor for MI in the general population. If confirmed in long-term cohort studies, these findings may lead to improved management, treatment, and outcomes for many patients who have had or are at high risk for MI.
